Thyroid inhibitory, antiperoxidative and hypoglycemic effects of stigmasterol isolated from Butea monosperma

Fitoterapia. 2009 Mar;80(2):123-6. doi: 10.1016/j.fitote.2008.12.002. Epub 2008 Dec 7.

Abstract

Stigmasterol, isolated from the bark of Butea monosperma was evaluated for its thyroid hormone and glucose regulatory efficacy in mice. Its administration at 2.6 mg/kg/d for 20 days reduced serum triiodothyronine (T(3)), thyroxin (T(4)) and glucose concentrations as well as the activity of hepatic glucose-6-phophatase (G-6-Pase) with a concomitant increase in insulin indicating its thyroid inhibiting and hypoglycemic properties. A decrease in the hepatic lipid peroxidation (LPO) and an increase in the activities of catalase (CAT), superoxide dismutase (SOD) and glutathione (GSH) suggested its antioxidative potential. The highest concentration tested (5.2 mg/kg) evoked pro-oxidative activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / isolation & purification
  • Antioxidants / pharmacology*
  • Antithyroid Agents / isolation & purification
  • Antithyroid Agents / pharmacology*
  • Blood Glucose
  • Butea / chemistry*
  • Catalase / metabolism
  • Glucose-6-Phosphatase / metabolism
  • Glutathione / metabolism
  • Hypoglycemic Agents / isolation & purification
  • Hypoglycemic Agents / pharmacology*
  • Insulin / blood
  • Lipid Peroxidation / drug effects
  • Mice
  • Plant Extracts / pharmacology*
  • Stigmasterol / chemistry
  • Stigmasterol / isolation & purification
  • Stigmasterol / pharmacology*
  • Superoxide Dismutase / metabolism
  • Thyroxine / blood
  • Triiodothyronine / blood

Substances

  • Antioxidants
  • Antithyroid Agents
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Plant Extracts
  • Triiodothyronine
  • Stigmasterol
  • Catalase
  • Superoxide Dismutase
  • Glucose-6-Phosphatase
  • Glutathione
  • Thyroxine